Sickle Cell Anemia is a disease with a strong vascular tropism. Beyond anemia, the pathophysiological mechanisms responsible for hemolysis, directly affect both acute and chronic vascular damages, thus resulting in a systemic disease. Understanding the different types of hemolysis underline the need for novel specific biomarkers. Targeted therapeutic approaches for these pathophysiological pathways are necessary to improve Sickle Cell patients' prognosis. Finally, given its complexity, Sickle Cell Disease is often used as a "proof of concept" for other pathologies. It seems likely that the rapidly evolving knowledge in this field will also benefit other diseases. © 2023 Société nationale française de médecine interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.
Keywords: Biomarkers; Biomarqueurs; Drépanocytose; Hemolysis; Hémolyse; Sickle Cell Disease; Vasculopathie; Vasculopathy.
Copyright © 2023 Société nationale française de médecine interne (SNFMI). Publié par Elsevier Masson SAS. Tous droits réservés.